Ifosfamide with Regional Hyperthermia in Soft-Tissue SarcomasSchlemmer M.a · Wendtner C.M.a · Issels R.D.a,b
aDepartment of Internal Medicine III, Klinikum Grosshadern Medical Center, Ludwig Maximilians University Munich, and bClinical Cooperation Group on Hyperthermia, GSF – National Research Center for Environment and Health, Institute of Molecular Immunology, Munich, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival. Therefore, systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS. The combination with regional hyperthermia as a new treatment strategy seems to open a new therapeutic window.
© 2003 S. Karger AG, Basel
Enzinger FM, Weiss SW: Soft Tissue Tumors. St Louis, Mosby, 1988.
- Pisters PWT, Harrison LB, Leung DHY et al: Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859–868.
- Yang JC, Chang AE, Baker AR et al: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197–203.
- Alvarenga JC, Ball ABS, Fisher C et al: Limitations of surgery in the treatment of sarcoma. Br J Surg 1991;78:912–916.
- Fein DA, Lee WR, Lanciano RM et al: Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: Do total dose, overall treatment time and the surgery-radiotherapy interval impact on local control? Int J Radiat Oncol Biol Phys 1995;32:969–976.
- Gaynor JJ, Tan CC, Casper ES et al: Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 1992;10:1317–1327.
- Bautista N, Su W, O’Connell TX: Retroperitoneal soft-tissue sarcomas: Prognosis and treatment of primary and recurrent disease. Am Surg 2000;66:832–836.
- Makela J, Kiviniemi H, Laitinen S: Prognostic factors predicting survival in the treatment of retroperitoneal sarcoma. Eur J Surg Oncol 2000;26:552–555.
- Falk M, Issels RD: Hyperthermia in oncology. Int J Hyperthermia 2000;17:1–16.
Nielsen OS, Horsman M, Overgaard J: A future for hyperthermia in cancer treatment? Eur J Cancer 2001;37:1587–1589.
Dewey WC: Interaction of heat with radiation and chemotherapy. Cancer Res 1984;44:4714–4720.
- Hyperthermia and the immune systeme (special issue). Int J Hyperthermia 2002;18:486–608.
- Prosnitz LR, Maguire P, Anderson JM et al: The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys 1999;45:941–949.
Gortzak E, Azzarelli A, Buesa J et al: A randomised phase II study on neoadjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096–1103.
Pezzi CM, Pollock RE, Evans HL et al: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1999;211:476–481.
- Rouesse JG, Friedman S, Sevin DM et al: Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer 1987;60:296–300.
- Pisters PWT, Patel SR, Varma DGK et al: Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: Long-term results form a single institution. J Clin Oncol 1997;15:3481–3487.
- Issels RD, Prenninger SW, Nagele A et al: Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: A phase II study. J Clin Oncol 1990;8:1818–1829.
Issels RD, Mittermüller J, Gerl A et al: Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: Updated report on 65 patients. J Cancer Res Clin Oncol 1991;117(suppl 4):141–147.
Issels RD, Abdel-Rahman S, Wendtner CM et al: Neoadjuvant chemotherapy combined with regional hyperthermia for locally advanced primary or recurrent high-risk soft tissue sarcomas of adults: Long-term results of a phase II study. Eur J Cancer 2001;37:1599–1608.
Wendtner CM, Abdel-Rahman S, Baumert J et al: Treatment of primary, recurrent or inadequately resected high-risk soft tissue sarcomas of adults: Results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001;37:1609–1616.
- Wendtner CM, Abdel-Rahman S, Krych M et al: Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2000;20:3156–3164.
EORTC 62961/ESHO RHT-95: Randomized study comparing neoadjuvant chemotherapy etoposide + ifosfamide + adriamycin (EIA) combined with regional hyperthermia versus neoadjuvant chemotherapy alone in the treatment of high-risk soft tissue sarcomas in adults. http://www.med.uni-muenchen.de/tzm/eortc
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.